Search

Your search keyword '"Piessevaux H"' showing total 299 results
Start Over Author "Piessevaux H"
299 results on '"Piessevaux H"'

9. Belgian consensus on irritable bowel syndrome

Author

Kindt, S, Louis, H, Deschepper, H, Arts, J, Caenepeel, P, De Looze, D, Gerkens, A, Holvoet, T, Latour, P, Mahler, T, Mokaddem, F, Nullens, S, Piessevaux, H, Poortmans, P, Rasschaert, G, Surmont, M, Vafa, H, Van Malderen, K, Vanuytsel, T, Wuestenberghs, Fabien, Tack, J, Kindt, S., Louis, H., De Schepper, H., Arts, J., CAENEPEEL, Philip, De Looze, D., Gerkens, A., Holvoet, T., Latour , P., Mahler, T., Mokaddem, F., Nullens, S., Piessevaux, H., Poortmans , P., Rasschaert, G., Surmont, M., Vafa, H., Van Malderen, K., Vanuytsel, T., Wuestenberghs, F., Tack, J., Clinical sciences, Gastroenterology, Pediatrics, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, and UCL - (MGD) Service de gastro-entérologie

Subjects
Diarrhea, irritable bowel syndrome, Consensus, Science & Technology, Gastroenterology & Hepatology, treatment, diagnosis, review, BILE-ACID MALABSORPTION, PLACEBO-CONTROLLED TRIAL, CHRONIC CONSTIPATION, OPEN-LABEL, CLINICAL-TRIAL, Delphi consensus, DOUBLE-BLIND, Belgium, ABDOMINAL-PAIN, FECAL MICROBIOTA TRANSPLANTATION, Humans, FUNCTIONAL GASTROINTESTINAL DISORDERS, Human medicine, Constipation, Life Sciences & Biomedicine, CELIAC GLUTEN SENSITIVITY
Abstract

BACKGROUND: Irritable bowel syndrome (IBS) is characterised by recurrent abdominal pain related to defaecation or associated with altered stool frequency or consistency. Despite its prevalence, major uncertainties in the diagnostic and therapeutic management persist in clinical practice. METHODS: A Delphi consensus was conducted by 20 experts from Belgium, and consisted of literature review and voting process on 78 statements. Grading of recommendations, assessment, development and evaluation criteria were applied to evaluate the quality of evidence. Consensus was defined as > 80 % agreement. RESULTS: Consensus was reached for 50 statements. The Belgian consensus agreed as to the multifactorial aetiology of IBS. According to the consensus abdominal discomfort also represents a cardinal symptom, while bloating and abdominal distension often coexist. IBS needs subtyping based on stool pattern. The importance of a positive diagnosis, relying on history and clinical examination is underlined, while additional testing should remain limited, except when alarm features are present. Explanation of IBS represents a crucial part of patient management. Lifestyle modification, spasmolytics and water-solube fibres are considered first-line agents. The low FODMAP diet, selected probiotics, cognitive behavioural therapy and specific treatments targeting diarrhoea and constipation are considered appropriate. There is a consensus to restrict faecal microbiota transplantation and gluten-free diet, while other treatments are strongly discouraged. CONCLUSIONS: A panel of Belgian gastroenterologists summarised the current evidence on the aetiology, symptoms, diagnosis and treatment of IBS with attention for the specificities of the Belgian healthcare system. ispartof: ACTA GASTRO-ENTEROLOGICA BELGICA vol:85 issue:2 pages:360-382 ispartof: location:Belgium status: accepted

Published
2022

12. Belgian consensus on irritable bowel syndrome.

Author

UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (MGD) Service de gastro-entérologie, Kindt, S, Louis, H, Deschepper, H, Arts, J, Caenepeel, P, De Looze, D, Gerkens, A, Holvoet, T, Latour, P, Mahler, T, Mokaddem, F, Nullens, S, Piessevaux, H, Poortmans, P, Rasschaert, G, Surmont, M, Vafa, H, Van Malderen, K, Vanuytsel, T, Wuestenberghs, Fabien, Tack, J, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (MGD) Service de gastro-entérologie, Kindt, S, Louis, H, Deschepper, H, Arts, J, Caenepeel, P, De Looze, D, Gerkens, A, Holvoet, T, Latour, P, Mahler, T, Mokaddem, F, Nullens, S, Piessevaux, H, Poortmans, P, Rasschaert, G, Surmont, M, Vafa, H, Van Malderen, K, Vanuytsel, T, Wuestenberghs, Fabien, and Tack, J

Abstract

Irritable bowel syndrome (IBS) is characterised by recurrent abdominal pain related to defaecation or associated with altered stool frequency or consistency. Despite its prevalence, major uncertainties in the diagnostic and therapeutic management persist in clinical practice. A Delphi consensus was conducted by 20 experts from Belgium, and consisted of literature review and voting process on 78 statements. Grading of recommendations, assessment, development and evaluation criteria were applied to evaluate the quality of evidence. Consensus was defined as > 80 % agreement. Consensus was reached for 50 statements. The Belgian consensus agreed as to the multifactorial aetiology of IBS. According to the consensus abdominal discomfort also represents a cardinal symptom, while bloating and abdominal distension often coexist. IBS needs subtyping based on stool pattern. The importance of a positive diagnosis, relying on history and clinical examination is underlined, while additional testing should remain limited, except when alarm features are present. Explanation of IBS represents a crucial part of patient management. Lifestyle modification, spasmolytics and water-solube fibres are considered first-line agents. The low FODMAP diet, selected probiotics, cognitive behavioural therapy and specific treatments targeting diarrhoea and constipation are considered appropriate. There is a consensus to restrict faecal microbiota transplantation and gluten-free diet, while other treatments are strongly discouraged. A panel of Belgian gastroenterologists summarised the current evidence on the aetiology, symptoms, diagnosis and treatment of IBS with attention for the specificities of the Belgian healthcare system.

Published
2022

26. Assessment of meal induced gastric accommodation by a satiety drinking test in health and in severe functional dyspepsia

Author

Tack, J, Caenepeel, P, Piessevaux, H, Cuomo, R, and Janssens, J

Subjects
Function tests (Medicine) -- Methods -- Evaluation -- Measurement -- Physiological aspects, Satiation -- Measurement -- Physiological aspects -- Methods, Dyspepsia -- Development and progression -- Prognosis, Indigestion -- Development and progression -- Prognosis, Health, Evaluation, Physiological aspects, Development and progression, Measurement, Prognosis, Methods
Abstract

Aims: Impaired gastric accommodation is a major pathophysiological mechanism in functional dyspepsia. The aim of the present work was to assess a satiety drinking test in the evaluation of accommodation [...]

Published
2003

40. Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial)

Author

Piessevaux, H., primary, Demey, W., additional, Bols, A., additional, Janssens, J., additional, Polus, M., additional, Rezaei Kalantari, H., additional, Laurent, S., additional, Demols, A., additional, Humblet, Y., additional, Deboever, G., additional, Kargar Samani, K., additional, Ferrante, M., additional, Monsaert, E., additional, Rondou, T., additional, van Laethem, J.-L., additional, and Tejpar, S., additional

Published
2018
Full Text
View/download PDF

47. Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer

Author

Geva R, Vecchione L, Tejpar S, Piessevaux H, Van Cutsem E, and Prenen H

Subjects
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, digestive system diseases
Abstract

Ravit Geva,1,2 Loredana Vecchione,2 Sabine Tejpar,2 Hubert Piessevaux,3 Eric Van Cutsem,2 Hans Prenen21Gastrointestinal Malignancies Service, Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; 2Department of Gastroenterology, Digestive Oncology Unit, University Hospitals Leuven, Leuven, Belgium; 3Department of Gastroenterology, Cliniques Universitaires Saint-Luc, Brussels, BelgiumPurpose: The combination of chemotherapy and bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor, is consistently being used as first- and second-line treatment in patients with metastatic colorectal cancer (mCRC). There is little data of the activity of bevacizumab in chemorefractory mCRC patients. The aim of this retrospective single center study was to evaluate the activity of bevacizumab combined with chemotherapy in this study population.Methods: Forty-six consecutive mCRC patients treated in the University Hospital Gasthuisberg (Leuven, Belgium) receiving bevacizumab in advanced lines following failure of conventional chemotherapy were included in this study. Treatment regimen consisted of bevacizumab 5 mg/kg in combination with leucovorin, 5-fluorouracil, and oxaliplatin (FOLFOX) or leucovorin, 5-fluorouracil, and irinotecan (FOLFIRI).Results: Bevacizumab plus chemotherapy was used in third-line treatment in eight (17%) patients and in fourth-line treatment or more in 38 patients (83%). All patients previously failed irinotecan-based chemotherapy, 44 (96%) failed oxaliplatin-based regimens, and 40 (87%) failed treatment with cetuximab. Bevacizumab was given in combination with irinotecan-based chemotherapy in 36 patients, oxaliplatin-based chemotherapy in nine patients, and with single agent 5-fluorouracil in one patient. Objective response was demonstrated in ten patients (22%) and disease control in 38 (83%) with a median progression-free survival of 8.9 months and a median overall survival of 13.8 months. Only four patients experienced grade III and above bevacizumab-related toxicity.Conclusion: Taking into account the retrospective nature of the study which can influence the selection of patients, bevacizumab given in advanced lines after failure of conventional chemotherapy and antiepidermal growth factor receptor agents can result in high disease control rates in patients with mCRC.Keywords: colorectal cancer, bevacizumab, chemorefractory

Published
2013

50. LAPAROSCOPIC ANTIREFLUX SURGERY VS ESOMEPRAZOLE TREATMENT FOR CHRONIC GERD – THE LOTUS RANDOMIZED CLINICAL TRIAL

Author

Miholic J, Hubmann R, Danis J, Tack J, Lerut T, Piessevaux H, Devière J, Buset M, Chioccioli C, De Looze D, Demoulin JC, Louis E, Ghilain JM, Maisin JM, Funch Jensen P, Nielsen J, Christensen L, Antonsen H, Lauritsen K, Jess P, Wallin L, Naver L, Galmiche JP, Letessier E, Zerbib F, Bonaz B, Bost R, Delchier JC, Fein M, Maroske J, Ell C, Hölscher A, Zornig C, Schneider JH, Hüttl T, Büchler M, Wehrmann U, Kemen M, Layer P, Fuchs KH, Kemen S, Hüppe D, Oddsdóttir M, Thjodleifsson B, Bonavina L, Ancona E, Morino M, Pignata G, Giurissa A, Rossi M, Cestari R, Gooszen H, Hatlebakk J, Tefera S, Johnsen G, Jahnsen J, Sandstad O, Stallemo A, Florholmen J, Tollåli G, Engström C, Liedman B, Lundell L, Babbs C, Attwood S., ROSATI , RICCARDO, Miholic, J, Hubmann, R, Danis, J, Tack, J, Lerut, T, Piessevaux, H, Devière, J, Buset, M, Chioccioli, C, De Looze, D, Demoulin, Jc, Louis, E, Ghilain, Jm, Maisin, Jm, Funch Jensen, P, Nielsen, J, Christensen, L, Antonsen, H, Lauritsen, K, Jess, P, Wallin, L, Naver, L, Galmiche, Jp, Letessier, E, Zerbib, F, Bonaz, B, Bost, R, Delchier, Jc, Fein, M, Maroske, J, Ell, C, Hölscher, A, Zornig, C, Schneider, Jh, Hüttl, T, Büchler, M, Wehrmann, U, Kemen, M, Layer, P, Fuchs, Kh, Kemen, S, Hüppe, D, Oddsdóttir, M, Thjodleifsson, B, Bonavina, L, Ancona, E, Morino, M, Pignata, G, Giurissa, A, Rossi, M, Rosati, Riccardo, Cestari, R, Gooszen, H, Hatlebakk, J, Tefera, S, Johnsen, G, Jahnsen, J, Sandstad, O, Stallemo, A, Florholmen, J, Tollåli, G, Engström, C, Liedman, B, Lundell, L, Babbs, C, and Attwood, S.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results